The size of the Europe blood culture tests market was valued at USD 16.31 billion in 2024. This market is expected to grow at a CAGR of 8.80% from 2025 to 2033 and be worth USD 34.84 billion by 2033 from USD 17.75 billion in 2025.
The availability of advanced diagnostics products and the presence of highly developed healthcare infrastructure in European countries like Germany, the UK, Switzerland, and France have further fueled the growth of the European blood culture tests market. Also, growing investments in R&D by manufacturers for new product development in this region is expected to propel the growth of the industry. Furthermore, increasing R&D investments by manufacturers for new product development in this region is expected to drive the growth of the industry.
Furthermore, the increasing number of patients and growing prevalence of hospitals due to increasing COVID-19 cases in European countries are fuelling the market growth in blood culture tests. Extensive usage of blood culture tests in hospitals, labs, reference labs, and other purposes is propelling the market's future. Growing product acceptance and launches are likely to fuel the blood culture tests market. With high growth in death rate and illness, the requirement for diagnostic procedures will accelerate the growth. According to WHO, thirty million people are affected by sepsis and resulting in 6 million deaths every year. High expenditure by singles towards healthcare and the existence of strong medical insurance are boosting the market.
The expensive nature of the highly automated blood testing lab instruments for productive diagnosis and regular approval procedures in the region are expected to impede the growth. However, a deficit of knowledge on technology's latest advancements is restraining the market’s growth rate. Lack of experienced lab technicians is restricting the market growth of blood culture over the period. Strict government guidelines for the enhancement and manufacturing of the diagnosis of products, including blood culture test products, hinder the market growth in the region.
Europe is just behind North America in leading the majority share in the global blood culture tests market and is expected to experience flourishing growth in the coming years. The rise in the occurrence of diseases like bloodstream infections, kidney disorders, and other organ infections is likely to drive the market growth. The rising older people population and escalating demand for blood culture tests are expected to boost the growth. Germany is leading the market with the highest CAGR of 4.4% in the European region. The country has experienced prominent growth in the area primarily due to enhanced healthcare infrastructure and the increasing pharmaceutical industry. Investments made by prominent key players in healthcare in research and development activities for new product development and integration of technological advancements among the medical devices are likely to bolster the growth in the market. Other countries like the UK, France, and Switzerland are expected to strengthen the market further in the near future.
The European blood culture tests market is dominated by companies like Becton, Dickinson, and Company, bioMérieux SA, Thermo Fisher Scientific Inc., Cepheid, Inc., Nanosphere Inc., IRIDICA, Beckman Coulter, Bruker Corporation, and T2 Biosystems.
This Europe blood culture tests market research report is segmented and sub-segmented into the following categories.
By Product
By Technology
By Application
By End User
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region